Risks and benefits of activated protein C treatment for severe sepsis.
D018806:APACHE; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D017277:Drug Approval; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012306:Risk; D018805:Sepsis / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D014481:United States
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated